November 8, 2018 / 12:26 AM / 8 months ago

Diabetes drugmakers must face claims over pancreatic cancer risk

A California appeals court reversed a grant of summary judgment to a group of drugmakers accused of failing to warn that their type 2 diabetes medications increased users’ risk of developing pancreatic cancer.

The claims against Merck Sharp & Dohme Corp, the maker of Janumet and Januvia; Novo Nordisk Inc, the manufacturer of Victoza; and AstraZeneca’s Amylin Pharmaceuticals, which produces Byetta, are not preempted by federal law, a unanimous three-judge panel of the California Court of Appeals in Los Angeles found on Tuesday.

To read the full story on Westlaw Practitioner Insights, click here:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below